News

QualTex Laboratories, a subsidiary of BioBridge, offers a variety of ways for you to stay connected with us and our subsidiaries. You can read our latest press releases or Annual Reports. Visit the Events Page to find out what’s coming up. You can watch a video clip from a newscast, view past events in the Photo Gallery or read industry news. For the social media enthusiast, the BioBridge family is known as “Connect for Life,” and can be found on FacebookTwitterLinkedIn and YouTube. Also, visit our blog here.

Media is welcome to contact the Corporate Communications Department for more information.

We offer:

  • 
Interviews with experts in their respective medical fields
  • Interviews with Life Links - community members touched by the services of BioBridge Global
  • Informative tours of the facility

Please contact;
Corporate Communications
Phone: (210) 731-5519
Mobile: (210) 296-9026
Email: crd@biobridgeglobal.org

Recent News Articles

July 12, 2016

As part of its commitment to ensuring the safest blood supply possible, the South Texas Blood & Tissue Center (STBTC) has begun testing blood donations for the Zika virus. STBTC is one of only a handful of blood centers in the nation currently testing for Zika.

“We believe this is the best way to safeguard the people of South Texas who need blood transfusions,” said Elizabeth Waltman, chief operating officer of STBTC. “Taking a precautionary approach will optimize patient safety and help maintain blood availability for everyone.”

Testing for the Zika virus is being done by QualTex Laboratories, which like STBTC is a subsidiary of San Antonio-based nonprofit BioBridge Global, with testing labs here and in Norcross, Georgia. Zika testing is being done in the QualTex labs in Georgia, because of space and capacity requirements for the testing equipment.

April 25, 2016

Community and health care leaders appealed to South Texans to donate blood for multiple reasons on April 25.

Elizabeth Waltman, chief operating officer of the South Texas Blood & Tissue Center, joined Mayor Ivy Taylor, Bexar County Judge Nelson Wolff and officials from San Antonio Metro Health Department, the San Antonio Chamber of Commerce and the U.S. Air Force on the steps of City Hall.

April 13, 2016

The last major outbreak of the Zika virus is helping scientists establish what they believe is a tie between the virus and a relatively rare neurological disorder.

From October 2013 to April 2014, approximately 32,000 people – two-thirds of the population of French Polynesia – consulted a doctor about a suspected infection of the Zika virus. Of those, 42 were diagnosed with the neurological condition known as Guillain-Barré syndrome.

In the United States and Europe, Guillain-Barré typically affects 1-2 people per 100,000 population. It usually is triggered by an infection like herpes, influenza of dengue, and it is fatal in about 5 percent of the cases.

Of the patients diagnosed with Guillain-Barré in French Polynesia, 88 percent had experienced symptoms of a Zika virus infection approximately six days before the neurological symptoms appeared. All the patients had Zika virus antibodies in their blood.

February 24, 2016

QualTex Laboratories is working with suppliers and companies affiliated with our parent organization BioBridge Global, and outside laboratories and regulatory agencies to support the development of an effective test for the Zika virus in blood components.

As soon as a test is available, QualTex will work on implementing it for both the South Texas Blood & Tissue Center and customers from coast to coast.

In the meantime, QualTex is monitoring information and sharing it with our customers. We have established a web page updated on a regular basis with news and notes from around the country and around the world.

December 30, 2015

A vaccination for a mosquito-borne virus that has re-emerged in the Caribbean is headed for phase 2 clinical trials.

The National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, is sponsoring trials of a vaccination for the chikungunya virus.

Phase 2 of the trial will enroll 400 adults in the Caribbean, where the virus has re-emerged. The chikungunya virus is spread by mosquito bites, and it can produce severe joint pain, fever and headache that typically last for a week but can persist for months or years.

There have been more than 621,000 cases reported in the Caribbean this year.

Pages